JAMA Articles Suggest Non-Inferiority Trials Are, In Fact, Sometimes Inferior
This article was originally published in The Gray Sheet
Executive Summary
Non-inferiority and equivalence trials are often poorly conducted and poorly reported, according to a series of articles in the Journal of the American Medical Association that could have particular implications for device firms
You may also be interested in...
FDA Defines Ground Rules For Evolving DES Clinical Trial Paradigm
Foreign drug-eluting stent trial strategies should be discussed with FDA at pre-IDE meetings to ensure that data outside the U.S. will be acceptable for premarket submissions, CDRH Division of Cardiovascular Devices Director Bram Zuckerman recommends
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.